Last reviewed · How we verify
U0267
U0267 is a small molecule drug that targets the molecular target.
U0267 is a small molecule drug that targets the molecular target. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | U0267 |
|---|---|
| Sponsor | Stiefel, a GSK Company |
| Drug class | small molecule |
| Target | molecular target |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action is not well understood, but it is believed to work by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies (PHASE3)
- Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- U0267 CI brief — competitive landscape report
- U0267 updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI